Cidara Therapeutics Inc. held its 2025 Annual Meeting of Stockholders on June 18, 2025. During the meeting, stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing the number of shares authorized for issuance by 2,880,000. Additionally, an amendment to the company's Amended and Restated Certificate of Incorporation was approved, increasing the authorized number of shares of Common Stock from 50,000,000 to 100,000,000. The stockholders also elected Jeffrey Stein, Ph.D., Bonnie Bassler, Ph.D., and Ryan Spencer as Class I Directors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cidara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001610618-25-000072), on June 20, 2025, and is solely responsible for the information contained therein.